[1]
|
Griguolo, G., Holgado, E., Cortes, J., Fasani, R., Pascual, T., Paré, L., et al. (2019) Abstract P6-17-08: Dynamics of Tumor-Infiltrating Lymphocytes (TILs) during Neoadjuvant Dual HER2 Blockade in HER2-Positive (HER2+) Breast Cancer in the Absence of Chemotherapy. Cancer Research, 79, P6-17-08.
https://doi.org/10.1158/1538-7445.SABCS18-P6-17-08
|
[2]
|
Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. (2000) Molecular Portraits of Human Breast Tumours. Nature, 406, 747-752. https://doi.org/10.1038/35021093
|
[3]
|
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human-Breast Cancer—Correlation of Relapse and Survival with Amplification of the HER-2 Neu Oncogene. Science, 235, 177-182.
https://doi.org/10.1126/science.3798106
|
[4]
|
Knauer, M., Cardoso, F., Wesseling, J., Bedard, P.L., Linn, S.C., Rutgers, E.J.T., et al. (2010) Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-Gene Prognosis Signature. British Journal of Cancer, 103, 1788-1793. https://doi.org/10.1038/sj.bjc.6605916
|
[5]
|
Konecny, G., Pauletti, G., Pegram, M., Bedard, P.L., Linn, S.C., Rutgers, E.J.T., et al. (2003) Quantitative Association between, HER-2/Neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer. Journal of the National Cancer Institute, 95, 142-153. https://doi.org/10.1093/jnci/95.2.142
|
[6]
|
Lal, P., Tan, L.K. and Chen, B.Y. (2005) Correlation of HER-2 Status with Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast Carcinomas. American Journal of Clinical Pathology, 123, 541-546.
https://doi.org/10.1309/YMJ3A83TB39MRUT9
|
[7]
|
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., et al. (2008) Relationship between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status with Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 26, 1059-1065.
https://doi.org/10.1200/JCO.2007.12.9437
|
[8]
|
Omarini, C., Bettelli, S., Caprera, C., Manfredini, S., Barbolini, M., Moscetti, L., et al. (2019) Differential Molecular Pathways Expression in HER2 Positive Early Breast Cancer According to Hormone Receptor Status. Journal of Cancer Research and Clinical Oncology, 145, 821-828. https://doi.org/10.1007/s00432-018-02833-8
|
[9]
|
Guo, L., Zhu, Q., Aisimutuola, M., Yilamu, D., Liu, S. and Jakulin, A. (2015) Expression and Prognostic Value of Estrogen Receptor Beta in Patients with Triple-Negative and Triple-Positive Breast Cancer. Experimental and Therapeutic Medicine, 9, 2147-2150. https://doi.org/10.3892/etm.2015.2380
|
[10]
|
Pinhel, I., Hills, M., Drury, S., Salter, J., Sumo, G., A’Hern, R., et al. (2012) ER and HER2 Expression Are Positively Correlated in HER2 Non-Overexpressing Breast Cancer. Breast Cancer Research, 14, Article No. R46.
https://doi.org/10.1186/bcr3145
|
[11]
|
Yang, H.-Y., Ma, D., Liu, Y.-R., Hu, X., Zhang, J., Wang, Z.-H., et al. (2018) Impact of Hormone Receptor Status and Distant Recurrence-Free Interval on Survival Benefits from Trastuzumab in HER2-Positive Metastatic Breast Cancer. Scientific Reports, 7, Article No. 1134. https://doi.org/10.1038/s41598-017-00663-1
|
[12]
|
Cortes, J. and Baselga, J. (2009) How to Treat Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Amplified Breast Cancer. Journal of Clinical Oncology, 27, 5492-5494. https://doi.org/10.1200/JCO.2009.23.8089
|
[13]
|
Llombart-Cussac, A., Cortes, J., Pare, L., Galván, P., Bermejo, B., Martínez, N., et al. (2017) HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib without Chemotherapy in Early-Stage HER2-Positive Breast Cancer (PAMELA): An Open-Label, Single-Group, Multicentre, Phase 2 Trial. The Lancet Oncology, 18, 545-554. https://doi.org/10.1016/S1470-2045(17)30021-9
|
[14]
|
Prat, A., Bianchini, G., Thomas, M., Belousov, A., Cheang, M.C.U., Koehler, A., et al. (2014) Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research, 20, 511-521. https://doi.org/10.1158/1078-0432.CCR-13-0239
|
[15]
|
Prat, A., Pascual, T. and Adamo, B. (2017) Intrinsic Molecular Subtypes of HER2+ Breast Cancer. Oncotarget, 8, 73362-73363. https://doi.org/10.18632/oncotarget.20629
|
[16]
|
Lambertini, M., Campbell, C., Gelber, R.D., Viale, G., McCullough, A., Hilbers, F., et al. (2019) Dissecting the Effect of Hormone Receptor Status in Patients with HER2-Positive Early Breast Cancer: Exploratory Analysis from the ALTTO (BIG 2-06) Randomized Clinical Trial. Breast Cancer Research and Treatment, 177, 103-114.
https://doi.org/10.1007/s10549-019-05284-y
|
[17]
|
Anderson, W.F., Chatterjee, N., Ershler, W.B. and Brawley, O.W. (2002) Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database. Breast Cancer Research and Treatment, 76, 27-36.
https://doi.org/10.1023/A:1020299707510
|
[18]
|
Rakha, E.A., El-Sayed, M.E., Green, A.R., Claire Paish, E., Powe, D.G., Gee, J., et al. (2007) Biologic and Clinical Characteristics of Breast Cancer with Single Hormone Receptor-Positive Phenotype. Journal of Clinical Oncology, 25, 4772-4778. https://doi.org/10.1200/JCO.2007.12.2747
|
[19]
|
Broglio, K.R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S.M., et al. (2016) Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer with Long-Term Outcomes A Meta-Analysis. JAMA Oncology, 2, 751-760. https://doi.org/10.1001/jamaoncol.2015.6113
|
[20]
|
The Cancer Genome Atlas Network (2012) Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61-70. https://doi.org/10.1038/nature11412
|
[21]
|
Tripathy, D., Kaufman, P.A., Brufsky, A.M., Mayer, M., Yood, M.U., Yoo, B., et al. (2013) First-Line Treatment Patterns and Clinical Outcomes in Patients with HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer from RegistHER. Oncologist, 18, 501-510. https://doi.org/10.1634/theoncologist.2012-0414
|
[22]
|
Loibl, S., De La Pena, L., Nekljudova, V., Zardavas, D., Denkert, C., Denkert, C., et al. (2017) Neoadjuvant Buparlisib plus Trastuzumab and Paclitaxel for Women with HER2+ Primary Breast Cancer: A Randomised, Double-Blind, Placebo-Controlled Phase II Trial (Neophoebe). European Journal of Cancer, 85, 133-145.
https://doi.org/10.1016/j.ejca.2017.08.020
|
[23]
|
Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., et al. (2016) Abstract S5-03: Final Analysis of WSG-ADAPT HER2+/HR+ Phase II Trial: Efficacy, Safety, and Predictive Markers for 12-Weeks of Neoadjuvant TDM1 with or without Endocrine Therapy versus Trastuzumab plus Endocrine Therapy in HER2-Positive Hormone-Receptor Positive Early Breast Cancer. Cancer Research, 76, S5-03.
https://doi.org/10.1158/1538-7445.SABCS15-S5-03
|
[24]
|
Untch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., et al. (2012) Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy (GeparQuinto, GBG 44): A Randomised Phase 3 Trial. The Lancet Oncology, 13, 135-144. https://doi.org/10.1016/S1470-2045(11)70397-7
|
[25]
|
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., Aura, C., De Azambuja, E., et al. (2010) Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. Cancer Research, 70, S3-3. https://doi.org/10.1158/0008-5472.SABCS10-S3-3
|
[26]
|
Hurvitz, S.A., Martin, M., Jung, K.H., Huang, C.-S., Harbeck, N., et al. (2019) Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes from the Phase III Kristine Study. Journal of Clinical Oncology, 37, 2206-2216. https://doi.org/10.1200/JCO.19.00882
|
[27]
|
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., et al. (2016) 5-Year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): A Multicentre, Open-Label, Phase 2 Randomised Trial. The Lancet Oncology, 17, 791-800. https://doi.org/10.1016/S1470-2045(16)00163-7
|
[28]
|
Cantini, L., Pistelli, M., Merloni, F., Fontana, A., Bertolini, I., De Angelis, C., et al. (2020) Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. Clinical Breast Cancer, 20, E89-E98. https://doi.org/10.1016/j.clbc.2019.06.008
|
[29]
|
Nitz, U.A., Gluz, O., Christgen, M., Grischke, E.-M., Augustin, D., Kuemmel, S., et al. (2017) De-Escalation Strategies in HER2-Positive Early Breast Cancer (EBC): Final Analysis of the WSG-ADAPT HER2+/HR− Phase II Trial: Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Dual Blockade with Trastuzumab and Pertuzumab ± Weekly Paclitaxel. Annals of Oncology, 28, 2768-2772. https://doi.org/10.1093/annonc/mdx494
|
[30]
|
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., et al. (2013) Follow-Up Results of NOAH, a Randomized Phase III Trial Evaluating Neoadjuvant Chemotherapy with Trastuzumab (CT+H) Followed by Adjuvant H versus CT Alone, in Patients with HER2-Positive Locally Advanced Breast Cancer. Journal of Clinical Oncology, 31, 503. https://doi.org/10.1200/jco.2013.31.15_suppl.503
|
[31]
|
Hurvitz, S.A., Martin, M., Symmans, W.F., Jung, K.H., Huang, C.-S., et al. (2018) Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy versus Trastuzumab Emtansine Plus Pertuzumab in Patients with HER2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Oncology, 19, 115-126.
https://doi.org/10.1016/S1470-2045(17)30716-7
|
[32]
|
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., et al. (2013) Pertuzumab Plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (Tryphaena). Annals of Oncology, 24, 2278-2284. https://doi.org/10.1093/annonc/mdt182
|
[33]
|
Untch, M., Von Minckwitz, G., Gerber, B., Schem, C., Rezai, M., Fasching, P.A., et al. (2018) Survival Analysis after Neoadjuvant Chemotherapy with Trastuzumab or Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology, 36, 1308-1316.
https://doi.org/10.1200/JCO.2017.75.9175
|
[34]
|
Rimawi, M.F., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Rodriguez, A.A., et al. (2013) Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and without Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726-1731. https://doi.org/10.1200/JCO.2012.44.8027
|
[35]
|
Sudhan, D.R., Schwarz, L.J., Guerrero-Zotano, A., Formisano, L., Nixon, M.J., Croessmann, S., et al. (2019) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research, 25, 771-783.
https://doi.org/10.1158/1078-0432.CCR-18-1131
|
[36]
|
Cameron, D., Piccart-Gebhart, M.J., Gelber, R.D., Procter, M., Goldhirsch, A., de Azambuja, E., et al. (2017) 11 Years’ Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer: Final Analysis of the HERceptin Adjuvant (HERA) Trial. Lancet, 389, 1195-1205. https://doi.org/10.1016/S0140-6736(16)32616-2
|
[37]
|
Piccart-Gebhart, M.J., Holmes, A.P., Baselga, J., De Azambuja, E., Dueck, A.C., Viale, G., et al. (2014) First Results from the Phase III ALTTO Trial (BIG 2-06; NCCTG Alliance N063D) Comparing One Year of Anti-HER2 Therapy with Lapatinib alone (L), Trastuzumab Alone (T), Their Sequence (T → L), or Their Combination (T Plus L) in the Adjuvant Treatment of HER2-Positive Early Breast Cancer (EBC). Journal of Clinical Oncology, 32, LBA4.
https://doi.org/10.1200/jco.2014.32.15_suppl.lba4
|
[38]
|
Goldhirsch, A., Gelber, R.D., Piccart-Gebhart, M.J., de Azambuja, E., Procter, M., Suter, T.M., et al. (2013) 2 Years versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): An Open-Label, Randomised Controlled Trial. Lancet, 382, 1021-1028. https://doi.org/10.1016/S0140-6736(13)61094-6
|
[39]
|
Moreno-Aspitia, A., Holmes, E.M., Jackisch, C., De Azambuja, E., Boyle, F., Hillman, D.W., et al. (2017) Updated Results from the Phase III ALTTO Trial (BIG 2-06; NCCTG (Alliance) N063D) Comparing One Year of Anti-HER2 Therapy with Lapatinib Alone (L), Trastuzumab Alone (T), Their Sequence (T → L) or Their Combination (L + T) in the Adjuvant Treatment of HER2-Positive Early Breast Cancer. Journal of Clinical Oncology, 35, 502-502.
https://doi.org/10.1200/JCO.2017.35.15_suppl.502
|
[40]
|
Martin, M., Holmes, F.A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., et al. (2017) Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncology, 18, 1688-1700.
https://doi.org/10.1016/S1470-2045(17)30717-9
|
[41]
|
Chan, A., Delaloge, S., Holmes, F.A., Moy, B., Iwata, H., Harvey, V.J., et al. (2016) Neratinib after Trastuzumab-Based Adjuvant Therapy in Patients with HER2-Positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncology, 17, 367-377.
https://doi.org/10.1016/S1470-2045(15)00551-3
|
[42]
|
Johnston, S.R.D., Hegg, R., Im, S.A., Park, I.H., Burdaeva, O., Kurteva, G., et al. (2018) Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade with Lapatinib Plus Trastuzumab in Combination with an Aromatase Inhibitor in Postmenopausal Women with HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. Journal of Clinical Oncology, 36, 741-748.
https://doi.org/10.1200/JCO.2017.74.7824
|
[43]
|
Krop, I.E., Lin, N.U., Blackwell, K., Guardino, E., Huober, J., Lu, M., et al. (2015) Trastuzumab Emtansine (T-DM1) versus Lapatinib Plus Capecitabine in Patients with HER2-Positive Metastatic Breast Cancer and Central Nervous System Metastases: A Retrospective, Exploratory Analysis in EMILIA. Annals of Oncology, 26, 113-119.
https://doi.org/10.1093/annonc/mdu486
|
[44]
|
Swain, S.M., Kim, S.B., Cortes, J., Ro, J., Semiglazov, V., Campone, M., et al. (2013) Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. Lancet Oncology, 14, 461-471.
https://doi.org/10.1016/S1470-2045(13)70130-X
|
[45]
|
Arpino, G., Ferrero, J.M., De La Haba-Rodriguez, J., Easton, V., Schuhmacher, C., Restuccia, E., et al. (2017) Abstract S3-04: Primary Analysis of Pertain: A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination with Trastuzumab Plus an Aromatase Inhibitor in First-Line Patients with HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer. Cancer Research, 77, S3-04. https://doi.org/10.1158/1538-7445.SABCS16-S3-04
|
[46]
|
Dieras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., et al. (2017) Trastuzumab Emtansine versus Capecitabine Plus Lapatinib in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (EMILIA): A Descriptive Analysis of Final Overall Survival Results from A Randomised, Open-Label, Phase 3 Trial. Lancet Oncology, 18, 732-742. https://doi.org/10.1016/S1470-2045(17)30312-1
|
[47]
|
Tolaney, S.M., Wardley, A.M., Zambelli, S., Hilton, J.F., Troso-Sandoval, T.A., Ricci, F., et al. (2020) Abemaciclib Plus Trastuzumab with or without Fulvestrant versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women with Hormone Receptor-Positive, HER2-Positive Advanced Breast Cancer (MonarcHER): A Randomised, Open-Label, Phase 2 Trial. The Lancet Oncology, 21, 763-775. https://doi.org/10.1016/S1470-2045(20)30112-1
|
[48]
|
Perez, E.A., Hurvitz, S.A., Amler, L.C., Mundt, K.E., Ng, V., Guardino, E., et al. (2014) Relationship between HER2 Expression and Efficacy with First-Line Trastuzumab Emtansine Compared with Trastuzumab Plus Docetaxel in TDM4450g: A Randomized Phase II Study of Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer. Breast Cancer Research, 16, Article No. R50. https://doi.org/10.1186/bcr3661
|
[49]
|
Burstein, H.J., Cirrincione, C.T., Barry, W.T., Chew, H.K., Tolaney, S.M., Lake, D.E., et al. (2014) Endocrine Therapy with or without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib for Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer—CALGB 40302 (Alliance). Journal of Clinical Oncology, 32, 3959-3966. https://doi.org/10.1200/JCO.2014.56.7941
|
[50]
|
Toi, M., Shao, Z., Hurvitz, S., Tseng, L.-M., Zhang, Q., Shen, K., et al. (2017) Efficacy and Safety of Everolimus in Combination with Trastuzumab and Paclitaxel in Asian Patients with HER2+ Advanced Breast Cancer in BOLERO-1. Breast Cancer Research, 19, Article No. 47. https://doi.org/10.1186/s13058-017-0839-0
|
[51]
|
Rimawi, M., Ferrero, J.-M., De La Haba-Rodriguez, J., Poole, C., De Placido, S., Kent Osborne, C., et al. (2018) First-Line Trastuzumab Plus an Aromatase Inhibitor, with or without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of Clinical Oncology, 36, 2826-2835.
https://doi.org/10.1200/JCO.2017.76.7863
|
[52]
|
Krop, I.E., Kim, S.B., Martin, A.G., LoRusso, P.M., Ferrero, J.-M., Badovinac-Crnjevic, T., et al. (2017) Trastuzumab Emtansine versus Treatment of Physician’s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial. The Lancet Oncology, 18, 743-754. https://doi.org/10.1016/S1470-2045(17)30313-3
|
[53]
|
Perez, E.A., Barrios, C., Eiermann, W., Toi, M., Im, Y.-H., Conte, P., et al. (2017) Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study. Journal of Clinical Oncology, 35, 141-148. https://doi.org/10.1200/JCO.2016.67.4887
|
[54]
|
Krop, I.E., Kim, S.-B., Gonzalez Martin, A., LoRusso, P.M., Ferrero, J.-M., Badovinac-Crnjevic, T., et al. (2017) Trastuzumab Emtansine versus Treatment of Physician’s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial. The Lancet Oncology, 18, 743-754. https://doi.org/10.1016/S1470-2045(17)30313-3
|
[55]
|
Krop, I.E., Kim, S.-B., Gonzalez-Martin, A., LoRusso, P.M., Ferrero, J.-M., Smitt, M., et al. (2014) Trastuzumab Emtansine versus Treatment of Physician’s Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 689-699.
https://doi.org/10.1016/S1470-2045(14)70178-0
|
[56]
|
Wilson, T.R., Yu, J., Lu, X., Spoerke, J.M., Xiao, Y., O’Brien, C., et al. (2016) The Molecular Landscape of High-Risk Early Breast Cancer: Comprehensive Biomarker Analysis of a Phase III Adjuvant Population. NPJ Breast Cancer, 2, Article No. 16022. https://doi.org/10.1038/npjbcancer.2016.22
|
[57]
|
Herrera-Abreu, M.T., Palafox, M., Asghar, U., Rivas, M.A., Cutts, R.J., Garcia-Murillas, I., et al. (2016) Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Research, 76, 2301-2313. https://doi.org/10.1158/0008-5472.CAN-15-0728
|
[58]
|
Scaltriti, M., Eichhorn, P.J., Cortes, J., Prudkin, L., Aura, C., Jiménez, J., et al. (2011) Cyclin E Amplification/Overexpression Is a Mechanism of Trastuzumab Resistance in HER2+ Breast Cancer Patients. Proceedings of the National Academy of Sciences of the United States of America, 108, 3761-3766.
https://doi.org/10.1073/pnas.1014835108
|